Patents in Class 424/133.100

Matches 1 - 50 out of 649

Match	Document	Document Title
1	7390491	Agents comprising midkine or an inhibitor thereof as active ingredient Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its...
2	7390489	Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody The present invention relates to a monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes , a hybridoma cell producing the monoclonal antibody, a test kit comprising...
3	7390486	PRO4381 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
4	7387776	Human monoclonal antibodies against CD30 Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of...
5	7384633	Human type antihuman IgE receptor antibody and fragment An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (FcεRI) having...
6	7381803	Humanized antibodies against CD3 The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric...
7	7381408	Methods for chemically synthesizing immunoglobulin chimeric proteins The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.
8	7381407	Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods...
9	7378094	Therapeutic uses of complement receptor 2 The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune...
10	7378092	Immunogenic compositions for induction of anti-tumor immunity The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at...
11	7371382	Methods of inhibiting α_vβ₃-mediated binding with α_vβ₃-specific antibodies The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to α V β 3 , or a functional fragment thereof. The invention also provides nucleic acid molecules...
12	7371379	Dosages for treatment with anti-ErbB2 antibodies The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or...
13	7371377	Antibodies to polypeptides homologous to VEGF and BMP1 The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor...
14	7368111	Human antibodies specific for TGFβ2 Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both,...
15	7368110	Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use Mesothelin ins a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present...
16	7364738	Monoclonal antibodies to the CLFA protein and method of use in treating infections Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus , including the active...
17	7364737	Human neutralizing monoclonal antibodies to respiratory syncytial virus Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also...
18	7364736	Antibodies to OPGL Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are...
19	7364732	Method for treating inflammation A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its...
20	7364731	Polypeptide variants A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326,327, 329, 331, 333...
21	7361344	Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective...
22	7361341	Methods of treating cancer using antibodies that immunospecifically bind to trail receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other...
23	7361338	Methods to inhibit growth of prostate cancer cells A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is...
24	7357927	Death domain containing receptors The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated...
25	7354586	Methods of treating arthritis and diabetic retinopathy with α_vβ₃-specific antibodies The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
26	7354585	Methods of treating coagulapathic or thrombotic disorders The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention...
27	7354584	Recombinant IL-9 antibodies The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and...
28	7348002	Inducible ligand for α1β1 integrin and uses The present invention is directed to the identification and use of agents, particularly peptides and monoclonal antibodies that disrupt the interaction between Collagen XIII and α1β1 integrin.
29	7348001	Tie1-binding ligands Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that...
30	7342110	Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced...
31	7341722	Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
32	7339033	PRO1481 The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
33	7338660	Methods of treating cancer and enhancing immune responses with antibodies that bind CD40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
34	7335744	Prostate cancer specific internalizing human antibodies This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The...
35	7335743	Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective...
36	7332582	Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation...
37	7332580	Bispecific single chain Fv antibody molecules and methods of use thereof Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
38	7332162	Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders A ligand derived from, e.g. a Fab fragment of, a monoclonal antibody obtainable from the cell line deposited with the Belgian Coordinated Collections of Micro-organisms under accession number LMBP...
39	7329406	Methods of treating psoriasis with αvβ3-specific antibodies The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
40	7323171	Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in...
41	7323170	Anti-CD80 antibodies The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from...
42	7321026	Framework-patched immunoglobulins Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described...
43	7320791	Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the...
44	7320790	Humanized antibodies Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the...
45	7320789	Antibody inhibitors of GDF-8 and uses thereof The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also...
46	7319139	TAG-72 specific CH2 domain deleted antibodies Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may...
47	7318923	Humanized anti-βantibodies Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the...
48	7318922	Anti-PRO5337 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
49	7318921	Therapeutic compositions that alter the immune response The invention is therapeutic methods and compositions that alter the immunogenicity of the host.
50	7314632	Pseudomonas exotoxin A-like chimeric immunogens This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using...

Matches 1 - 50 out of 649

1 2 3 4 5 6 7 8 9 10 11 12 13 >